This is a table of adjective/noun combinations and their frequencies from sentences in your study carrel. Use it to search & browse the list to learn more about your study carrel.
adjective | noun | frequency |
---|---|---|
- | cov-2 | 106435 |
- | cov | 34524 |
respiratory | syndrome | 21198 |
novel | coronavirus | 12894 |
covid-19 | patients | 8729 |
immune | response | 4948 |
- | cell | 4056 |
viral | rna | 3305 |
covid-19 | infection | 3299 |
- | sars | 3105 |
- | time | 3097 |
viral | infection | 2857 |
immune | responses | 2765 |
- | protein | 2540 |
- | analysis | 2471 |
human | coronavirus | 2381 |
viral | infections | 2276 |
new | coronavirus | 1943 |
covid-19 | cases | 1930 |
covid-19 | . | 1857 |
severe | disease | 1855 |
- | coronavirus | 1815 |
- | risk | 1588 |
respiratory | disease | 1546 |
human | ace2 | 1421 |
inflammatory | response | 1395 |
severe | cases | 1359 |
- | infection | 1271 |
humans | . | 1180 |
respiratory | viruses | 1178 |
immune | cells | 1147 |
high | risk | 1061 |
higher | risk | 1024 |
viral | proteins | 1024 |
severe | covid-19 | 993 |
respiratory | infections | 921 |
available | . | 875 |
first | case | 864 |
clinical | studies | 807 |
negative | . | 792 |
- | cells | 752 |
clinical | samples | 738 |
respiratory | infection | 723 |
positive | results | 720 |
several | studies | 695 |
positive | . | 692 |
specific | antibodies | 654 |
negative | results | 639 |
human | cells | 624 |
other | studies | 599 |
clinical | data | 593 |
positive | patients | 575 |
inflammatory | responses | 560 |
severe | patients | 553 |
respiratory | virus | 539 |
other | viruses | 529 |
covid-19 | disease | 527 |
positive | sars | 506 |
covid-19 | patient | 494 |
respiratory | diseases | 494 |
positive | cases | 475 |
severe | sars | 474 |
- | ace2 | 469 |
positive | samples | 448 |
others | . | 438 |
viral | protein | 438 |
human | sars | 432 |
available | data | 419 |
- | virus | 393 |
first | time | 391 |
viral | diseases | 384 |
antiviral | treatment | 382 |
respiratory | samples | 381 |
new | virus | 372 |
inflammatory | syndrome | 365 |
potential | risk | 357 |
- | patient | 345 |
antiviral | response | 341 |
severe | coronavirus | 341 |
immune | cell | 339 |
new | cases | 337 |
positive | result | 336 |
specific | antibody | 324 |
other | patients | 318 |
covid-19 | infections | 314 |
human | infection | 312 |
novel | virus | 308 |
human | cell | 299 |
low | . | 293 |
first | cases | 293 |
human | proteins | 289 |
novel | sars | 281 |
other | coronavirus | 272 |
potential | treatment | 269 |
severe | infection | 269 |
human | disease | 267 |
clinical | study | 253 |
respiratory | coronavirus | 249 |
- | response | 246 |
- | analyses | 245 |
negative | samples | 242 |
- | rna | 240 |
inflammatory | diseases | 230 |
human | cases | 226 |
other | diseases | 226 |
low | risk | 221 |
inflammatory | cells | 220 |
covid-19 | treatment | 220 |
- | day | 219 |
important | . | 212 |
new | disease | 212 |
- | patients | 211 |
viral | disease | 210 |
lower | risk | 197 |
- | infections | 196 |
different | cell | 195 |
high | . | 194 |
clinical | disease | 193 |
other | . | 193 |
negative | result | 190 |
- | case | 189 |
- | treatment | 189 |
other | sars | 189 |
negative | sars | 183 |
potential | . | 182 |
acute | infection | 179 |
other | rna | 174 |
different | time | 173 |
human | infections | 169 |
specific | treatment | 169 |
several | days | 168 |
such | patients | 164 |
- | covid-19 | 158 |
first | day | 155 |
positive | cells | 155 |
highest | risk | 153 |
other | proteins | 153 |
human | protein | 152 |
acute | sars | 149 |
antiviral | responses | 146 |
first | patient | 143 |
different | sars | 142 |
- | antibody | 140 |
first | study | 140 |
severe | infections | 139 |
first | sars | 136 |
specific | cell | 135 |
human | diseases | 134 |
inflammatory | cell | 133 |
negative | patients | 132 |
new | infections | 132 |
new | sars | 132 |
early | treatment | 130 |
human | . | 129 |
specific | sars | 129 |
potential | sars | 128 |
clinical | treatment | 125 |
novel | viruses | 119 |
potential | risks | 119 |
different | viruses | 117 |
clinical | analysis | 116 |
different | . | 115 |
different | studies | 113 |
first | covid-19 | 110 |
such | cases | 110 |
several | cases | 109 |
- | sample | 105 |
human | antibody | 103 |
antiviral | treatments | 102 |
other | cases | 102 |
such | studies | 102 |
other | infections | 101 |
- | disease | 100 |
potential | treatments | 100 |
early | infection | 98 |
- | proteins | 96 |
other | cells | 96 |
human | studies | 92 |
clinical | case | 92 |
antivirals | . | 91 |
clinical | cases | 89 |
early | studies | 88 |
positive | sample | 88 |
clinical | response | 87 |
inflammatory | protein | 87 |
available | sars | 85 |
earlier | studies | 85 |
severe | . | 85 |
human | viruses | 84 |
positive | patient | 83 |
inflammatory | disease | 82 |
specific | . | 82 |
higher | case | 79 |
several | viruses | 79 |
other | virus | 77 |
different | times | 77 |
early | sars | 76 |
other | cell | 76 |
higher | . | 75 |
large | sample | 75 |
human | antibodies | 74 |
different | samples | 73 |
larger | sample | 73 |
severe | diseases | 73 |
high | case | 71 |
new | viruses | 70 |
important | risk | 69 |
new | data | 69 |
new | infection | 69 |
clinical | sample | 68 |
early | cases | 68 |
several | times | 68 |
higher | ace2 | 67 |
high | sars | 67 |
respiratory | syndromes | 65 |
severe | case | 65 |
covid-19 | risk | 64 |
covid-19 | treatments | 64 |
lower | . | 64 |
viral | cell | 64 |
earlier | . | 63 |
positive | antibody | 63 |
several | sars | 62 |
different | patients | 61 |
larger | studies | 61 |
negatives | . | 61 |
other | risk | 61 |
several | patients | 61 |
acute | covid-19 | 60 |
viral | response | 60 |
novel | disease | 59 |
human | samples | 59 |
acute | infections | 58 |
covid-19 | case | 58 |
early | days | 58 |
new | treatment | 58 |
positives | . | 57 |
human | patients | 56 |
positive | case | 56 |
specific | proteins | 56 |
different | virus | 55 |
first | days | 55 |
high | infection | 55 |
higher | antibody | 55 |
other | patient | 55 |
specific | treatments | 55 |
negative | cases | 54 |
other | treatments | 53 |
- | antibodies | 53 |
positive | covid-19 | 52 |
early | data | 52 |
clinical | results | 51 |
large | . | 51 |
several | case | 51 |
clinical | sars | 50 |
covid-19 | virus | 50 |
other | data | 50 |
first | . | 49 |
other | samples | 49 |
new | diseases | 49 |
high | ace2 | 49 |
other | study | 49 |
early | response | 49 |
early | . | 49 |
different | disease | 49 |
antiviral | protein | 49 |
different | patient | 48 |
other | disease | 48 |
respiratory | sample | 48 |
high | antibody | 47 |
largest | rna | 46 |
several | diseases | 46 |
positive | rna | 45 |
acute | disease | 44 |
different | proteins | 44 |
first | infection | 44 |
specific | rna | 44 |
high | virus | 43 |
specific | ace2 | 43 |
different | results | 42 |
such | data | 42 |
new | studies | 42 |
different | coronavirus | 42 |
- | study | 42 |
clinical | syndrome | 42 |
different | diseases | 41 |
earlier | study | 41 |
early | case | 41 |
specific | data | 41 |
specific | protein | 41 |
higher | infection | 40 |
human | virus | 40 |
inflammatory | treatments | 40 |
different | days | 39 |
large | study | 39 |
other | case | 39 |
potential | covid-19 | 39 |
potential | infection | 39 |
new | patients | 38 |
negative | sample | 38 |
early | disease | 38 |
- | studied | 37 |
larger | study | 37 |
new | treatments | 37 |
other | day | 37 |
respiratory | cells | 37 |
respiratory | sars | 37 |
large | rna | 36 |
specific | risk | 36 |
covid-19 | coronavirus | 35 |
higher | risks | 35 |
human | rna | 35 |
several | proteins | 34 |
such | antibodies | 34 |
specific | case | 34 |
lower | case | 34 |
different | protein | 34 |
clinical | risk | 34 |
clinical | syndromes | 33 |
earlier | time | 33 |
early | study | 33 |
first | results | 33 |
- | days | 32 |
antiviral | proteins | 32 |
other | treatment | 32 |
other | protein | 31 |
other | covid-19 | 31 |
viral | treatment | 31 |
covid-19 | samples | 31 |
novel | protein | 31 |
early | time | 31 |
novel | covid-19 | 30 |
several | rna | 30 |
potential | cases | 30 |
available | studies | 30 |
higher | sars | 30 |
early | covid-19 | 30 |
anti | sars | 29 |
covid-19 | response | 29 |
several | cell | 29 |
specific | responses | 29 |
specific | virus | 29 |
low | antibody | 28 |
first | coronavirus | 28 |
several | risk | 28 |
human | cov | 28 |
novel | treatment | 28 |
different | treatment | 28 |
- | data | 28 |
different | sample | 28 |
new | covid-19 | 28 |
different | cells | 28 |
different | treatments | 27 |
high | protein | 27 |
large | studies | 27 |
low | sample | 27 |
specific | disease | 27 |
- | result | 26 |
- | viruses | 26 |
earlier | sars | 26 |
first | studies | 26 |
highest | . | 26 |
low | virus | 26 |
such | viruses | 26 |
specific | cells | 25 |
respiratory | rna | 25 |
other | antibodies | 25 |
new | case | 25 |
antiviral | antibodies | 25 |
available | case | 24 |
specific | response | 24 |
human | covid-19 | 23 |
humans | sars | 23 |
such | cells | 23 |
such | study | 23 |
such | treatment | 23 |
viral | antibodies | 23 |
viral | . | 22 |
such | samples | 22 |
specific | studies | 22 |
specific | coronavirus | 22 |
new | study | 22 |
lower | infection | 22 |
negative | patient | 22 |
higher | virus | 22 |
different | rna | 22 |
different | antibodies | 22 |
human | data | 22 |
novel | case | 21 |
specific | patient | 21 |
specific | infection | 21 |
positive | virus | 21 |
positive | response | 21 |
such | infections | 21 |
low | case | 21 |
inflammatory | proteins | 21 |
different | study | 21 |
different | response | 21 |
acute | treatment | 21 |
acute | patients | 21 |
viral | sars | 20 |
such | diseases | 20 |
several | virus | 20 |
lower | ace2 | 20 |
largest | case | 20 |
human | case | 20 |
first | patients | 20 |
- | syndrome | 20 |
antiviral | . | 19 |
covid-19 | antibody | 19 |
first | data | 19 |
largest | study | 19 |
novel | infection | 19 |
other | infection | 19 |
low | infection | 18 |
lower | virus | 18 |
different | ace2 | 18 |
high | disease | 18 |
early | results | 18 |
- | sampled | 18 |
available | treatment | 18 |
covid-19 | results | 18 |
clinical | covid-19 | 18 |
lower | antibody | 17 |
- | times | 17 |
viral | responses | 17 |
severe | patient | 17 |
other | antibody | 17 |
new | syndrome | 17 |
negative | rna | 17 |
negative | antibody | 17 |
negative | cells | 17 |
low | sars | 17 |
low | ace2 | 17 |
large | patient | 17 |
important | protein | 17 |
higher | covid-19 | 17 |
different | infection | 17 |
different | covid-19 | 17 |
highest | case | 16 |
viral | samples | 16 |
potential | virus | 16 |
novel | cell | 16 |
large | protein | 16 |
human | patient | 16 |
clinical | infection | 16 |
higher | disease | 16 |
first | antibody | 16 |
first | analysis | 16 |
different | antibody | 16 |
clinical | patient | 16 |
viral | treatments | 15 |
respiratory | . | 15 |
inflammatory | treatment | 15 |
potential | antibody | 15 |
lower | sars | 15 |
low | disease | 15 |
different | data | 15 |
important | data | 15 |
- | diseases | 15 |
immune | . | 15 |
- | cases | 15 |
earlier | virus | 15 |
human | response | 15 |
new | cells | 14 |
several | protein | 14 |
respiratory | treatments | 14 |
positive | responses | 14 |
positive | days | 14 |
novel | syndrome | 14 |
positive | cell | 14 |
new | . | 14 |
large | case | 14 |
different | risk | 14 |
available | samples | 14 |
acute | diseases | 14 |
- | studies | 14 |
new | patient | 14 |
new | rna | 13 |
such | . | 13 |
specific | cases | 13 |
potential | disease | 13 |
positive | infection | 13 |
positive | antibodies | 13 |
other | sample | 13 |
larger | samples | 13 |
human | study | 13 |
highest | infection | 13 |
highest | ace2 | 13 |
first | sample | 13 |
early | times | 13 |
antiviral | antibody | 13 |
inflammatory | syndromes | 13 |
potential | coronavirus | 12 |
such | treatments | 12 |
such | risk | 12 |
such | analysis | 12 |
specific | diseases | 12 |
several | covid-19 | 12 |
several | coronavirus | 12 |
specific | analysis | 12 |
other | analyses | 12 |
high | covid-19 | 12 |
earlier | treatment | 12 |
covid-19 | diseases | 12 |
available | rna | 12 |
- | results | 12 |
larger | patient | 12 |
such | protein | 11 |
novel | treatments | 11 |
respiratory | cell | 11 |
several | disease | 11 |
specific | time | 11 |
such | analyses | 11 |
such | time | 11 |
such | results | 11 |
such | risks | 11 |
such | virus | 11 |
viral | antibody | 11 |
viral | syndrome | 11 |
new | sample | 11 |
novel | rna | 11 |
immune | diseases | 11 |
lowest | risk | 11 |
clinical | treatments | 11 |
low | protein | 11 |
- | . | 11 |
- | samples | 11 |
available | antibodies | 11 |
clinical | infections | 11 |
acute | coronavirus | 11 |
earliest | time | 11 |
early | antibody | 11 |
high | risks | 11 |
highest | sars | 11 |
large | proteins | 11 |
important | study | 10 |
specific | viruses | 10 |
respiratory | treatment | 10 |
potentials | . | 10 |
novel | diseases | 10 |
new | cell | 10 |
negative | covid-19 | 10 |
acute | virus | 10 |
first | rna | 10 |
first | cell | 10 |
earliest | cases | 10 |
covid-19 | studies | 10 |
covid-19 | risks | 10 |
- | al | 10 |
non | covid-19 | 9 |
other | time | 9 |
larger | case | 9 |
large | cell | 9 |
novel | data | 9 |
important | result | 9 |
respiratory | patients | 9 |
several | samples | 9 |
such | case | 9 |
such | disease | 9 |
such | sars | 9 |
inflammatory | . | 9 |
early | samples | 9 |
important | proteins | 9 |
different | responses | 9 |
human | responses | 9 |
covid-19 | covid-19 | 9 |
different | case | 9 |
different | infections | 9 |
clinical | responses | 9 |
earliest | . | 9 |
early | patients | 9 |
first | response | 9 |
higher | protein | 9 |
important | virus | 8 |
such | proteins | 8 |
specific | covid-19 | 8 |
potential | patients | 8 |
potential | ace2 | 8 |
other | results | 8 |
other | ace2 | 8 |
new | risks | 8 |
lowest | . | 8 |
new | results | 8 |
important | coronavirus | 8 |
high | rna | 8 |
high | patient | 8 |
first | protein | 8 |
early | virus | 8 |
earlier | times | 8 |
earlier | coronavirus | 8 |
different | cases | 8 |
covid-19 | antibodies | 8 |
potential | infections | 7 |
low | response | 7 |
negative | cell | 7 |
negative | virus | 7 |
new | antibody | 7 |
other | risks | 7 |
positive | ace2 | 7 |
specific | study | 7 |
severe | risk | 7 |
specific | risks | 7 |
specific | sample | 7 |
immune | proteins | 7 |
viral | studies | 7 |
viral | syndromes | 7 |
important | cell | 7 |
early | analysis | 7 |
immune | disease | 7 |
earliest | sars | 7 |
highest | antibody | 7 |
acute | response | 7 |
antiviral | infection | 7 |
available | protein | 7 |
available | treatments | 7 |
available | virus | 7 |
acute | . | 7 |
first | studied | 7 |
first | treatment | 7 |
first | virus | 7 |
high | response | 7 |
early | infections | 7 |
low | cells | 6 |
potential | case | 6 |
low | rna | 6 |
lower | protein | 6 |
novel | . | 6 |
other | times | 6 |
positive | coronavirus | 6 |
several | treatments | 6 |
several | antibodies | 6 |
several | treatment | 6 |
severe | virus | 6 |
specific | infections | 6 |
such | responses | 6 |
low | covid-19 | 6 |
novel | proteins | 6 |
largest | studies | 6 |
first | result | 6 |
largest | sample | 6 |
antiviral | studies | 6 |
available | covid-19 | 6 |
earlier | cases | 6 |
first | infections | 6 |
available | patient | 6 |
high | cell | 6 |
important | infection | 6 |
important | results | 6 |
antiviral | results | 6 |
larger | protein | 6 |
largest | protein | 6 |
several | infections | 5 |
lower | responses | 5 |
negative | infections | 5 |
new | risk | 5 |
novel | ace2 | 5 |
novel | infections | 5 |
other | responses | 5 |
potential | responses | 5 |
potential | studies | 5 |
such | antibody | 5 |
several | patient | 5 |
several | time | 5 |
severe | syndromes | 5 |
specific | analyses | 5 |
specific | times | 5 |
lower | cell | 5 |
such | infection | 5 |
such | times | 5 |
viral | sample | 5 |
lower | response | 5 |
potential | protein | 5 |
large | treatment | 5 |
covid-19 | viruses | 5 |
large | sars | 5 |
- | et | 5 |
- | treatments | 5 |
available | results | 5 |
available | time | 5 |
clinical | . | 5 |
clinical | diseases | 5 |
clinical | patients | 5 |
acute | cases | 5 |
earlier | analysis | 5 |
early | risk | 5 |
first | antibodies | 5 |
first | disease | 5 |
highest | virus | 5 |
human | sample | 5 |
important | sars | 5 |
earlier | data | 5 |
large | samples | 5 |
negative | antibodies | 4 |
novel | antibody | 4 |
non | sars | 4 |
new | analysis | 4 |
negative | studies | 4 |
negative | data | 4 |
low | patient | 4 |
lower | risks | 4 |
lower | disease | 4 |
lower | covid-19 | 4 |
low | cell | 4 |
largest | virus | 4 |
novel | studies | 4 |
novel | risk | 4 |
several | data | 4 |
others | studies | 4 |
positive | time | 4 |
positives | results | 4 |
positives | samples | 4 |
potential | rna | 4 |
potential | study | 4 |
respiratory | responses | 4 |
several | ace2 | 4 |
several | cells | 4 |
several | infection | 4 |
specific | results | 4 |
viral | cases | 4 |
largest | risk | 4 |
largest | sars | 4 |
important | diseases | 4 |
larger | sars | 4 |
early | patient | 4 |
larger | . | 4 |
acute | antibody | 4 |
available | coronavirus | 4 |
clinical | analyses | 4 |
covid-19 | data | 4 |
covid-19 | study | 4 |
different | risks | 4 |
earlier | results | 4 |
earliest | case | 4 |
earliest | days | 4 |
earliest | samples | 4 |
early | analyses | 4 |
earlier | infection | 4 |
early | proteins | 4 |
- | responses | 4 |
large | virus | 4 |
early | responses | 4 |
large | data | 4 |
important | viruses | 4 |
important | treatment | 4 |
important | patient | 4 |
higher | time | 4 |
higher | rna | 4 |
higher | cell | 4 |
higher | antibodies | 4 |
high | time | 4 |
newer | data | 3 |
other | syndromes | 3 |
other | studied | 3 |
other | cov-2 | 3 |
other | analysis | 3 |
newest | coronavirus | 3 |
lower | rna | 3 |
negative | response | 3 |
negative | days | 3 |
negative | day | 3 |
negative | case | 3 |
lowest | time | 3 |
low | results | 3 |
positive | data | 3 |
others | sars | 3 |
such | sample | 3 |
positive | disease | 3 |
positive | protein | 3 |
potential | analysis | 3 |
potential | response | 3 |
potential | results | 3 |
several | study | 3 |
severe | risks | 3 |
severe | treatment | 3 |
specific | patients | 3 |
such | cell | 3 |
such | response | 3 |
such | rna | 3 |
large | coronavirus | 3 |
viral | ace2 | 3 |
viral | analysis | 3 |
larger | rna | 3 |
novel | analyses | 3 |
large | antibody | 3 |
early | result | 3 |
important | studies | 3 |
acute | patient | 3 |
acute | responses | 3 |
acute | samples | 3 |
available | ace2 | 3 |
covid-19 | proteins | 3 |
covid-19 | result | 3 |
covid-19 | resulting | 3 |
covid-19 | sample | 3 |
earlier | case | 3 |
earlier | disease | 3 |
earliest | patients | 3 |
earliest | studies | 3 |
early | protein | 3 |
antiviral | data | 3 |
first | analyses | 3 |
higher | coronavirus | 3 |
important | disease | 3 |
first | proteins | 3 |
immune | study | 3 |
human | treatment | 3 |
highest | rna | 3 |
higher | response | 3 |
immune | studies | 3 |
higher | % | 3 |
first | samples | 3 |
high | responses | 3 |
first | sampled | 3 |
high | cells | 3 |
high | treatment | 3 |
lowest | virus | 2 |
negative | disease | 2 |
negative | responses | 2 |
negative | risk | 2 |
new | protein | 2 |
new | ace2 | 2 |
newer | studies | 2 |
novel | cases | 2 |
lowest | case | 2 |
novel | study | 2 |
lowest | sars | 2 |
largest | viruses | 2 |
lowest | antibody | 2 |
lower | treatment | 2 |
lower | sample | 2 |
lower | patient | 2 |
low | coronavirus | 2 |
low | antibodies | 2 |
largest | cases | 2 |
larger | proteins | 2 |
larger | data | 2 |
larger | cells | 2 |
positive | infections | 2 |
others | resulted | 2 |
severe | response | 2 |
positive | studies | 2 |
important | treatments | 2 |
such | patient | 2 |
such | ace2 | 2 |
specific | samples | 2 |
specific | result | 2 |
specific | days | 2 |
specific | day | 2 |
severest | cases | 2 |
severer | disease | 2 |
severe | data | 2 |
several | risks | 2 |
several | responses | 2 |
several | . | 2 |
respiratory | risk | 2 |
respiratory | response | 2 |
potential | time | 2 |
potential | result | 2 |
potential | proteins | 2 |
potential | data | 2 |
potential | cell | 2 |
potential | antibodies | 2 |
positive | viruses | 2 |
large | covid-19 | 2 |
earlier | cov | 2 |
important | time | 2 |
available | infection | 2 |
different | result | 2 |
different | cov-2 | 2 |
different | analyses | 2 |
covid-19 | syndromes | 2 |
clinical | virus | 2 |
clinical | time | 2 |
clinical | rna | 2 |
clinical | antibody | 2 |
available | viruses | 2 |
available | sample | 2 |
available | cell | 2 |
earliest | antibody | 2 |
available | cases | 2 |
available | antibody | 2 |
antivirals | studied | 2 |
antiviral | diseases | 2 |
antiviral | coronavirus | 2 |
anti | coronavirus | 2 |
acute | syndrome | 2 |
- | timed | 2 |
- | syndromes | 2 |
important | cells | 2 |
earlier | days | 2 |
- | sampling | 2 |
earliest | day | 2 |
higher | responses | 2 |
earliest | disease | 2 |
important | antibodies | 2 |
immune | protein | 2 |
immune | patients | 2 |
humans | resulting | 2 |
human | results | 2 |
highest | responses | 2 |
highest | disease | 2 |
higher | treatment | 2 |
higher | sample | 2 |
important | antibody | 2 |
higher | patient | 2 |
early | sampled | 2 |
higher | day | 2 |
early | ace2 | 2 |
early | coronavirus | 2 |
earliest | study | 2 |
first | cells | 2 |
first | et | 2 |
first | resulted | 2 |
high | % | 2 |
negative | time | 1 |
new | result | 1 |
negatives | resulting | 1 |
negatives | results | 1 |
new | analyses | 1 |
new | cov | 1 |
new | day | 1 |
new | proteins | 1 |
new | responses | 1 |
negatives | cases | 1 |
newer | infections | 1 |
new | samples | 1 |
new | studied | 1 |
new | time | 1 |
newer | diseases | 1 |
newer | study | 1 |
newer | treatments | 1 |
newer | viruses | 1 |
newest | disease | 1 |
newest | sars | 1 |
negative | syndrome | 1 |
novel | analysis | 1 |
non | coronavirus | 1 |
lower | cases | 1 |
negative | study | 1 |
negative | ace2 | 1 |
novel | cov | 1 |
largest | analysis | 1 |
largest | cell | 1 |
largest | coronavirus | 1 |
low | % | 1 |
low | et | 1 |
low | infections | 1 |
low | resulting | 1 |
low | risks | 1 |
low | samples | 1 |
low | treatment | 1 |
lower | analysis | 1 |
lower | antibodies | 1 |
lower | coronavirus | 1 |
lower | infections | 1 |
lowest | ace2 | 1 |
lowest | cell | 1 |
lowest | infection | 1 |
lowest | responses | 1 |
lowest | risks | 1 |
lows | . | 1 |
novel | antibodies | 1 |
potential | sample | 1 |
novel | cov-2 | 1 |
severe | syndrome | 1 |
respiratory | results | 1 |
several | al | 1 |
several | analyses | 1 |
several | antibody | 1 |
several | results | 1 |
several | sample | 1 |
several | syndromes | 1 |
severe | responses | 1 |
severe | samples | 1 |
severe | studies | 1 |
severe | time | 1 |
novel | risks | 1 |
severer | covid-19 | 1 |
specific | syndrome | 1 |
such | covid-19 | 1 |
viral | al | 1 |
viral | cells | 1 |
viral | coronavirus | 1 |
viral | covid-19 | 1 |
viral | et | 1 |
viral | result | 1 |
viral | risk | 1 |
respiratory | patient | 1 |
respiratory | cases | 1 |
respiratory | case | 1 |
larger | virus | 1 |
novel | times | 1 |
other | cov | 1 |
other | days | 1 |
other | response | 1 |
other | sampled | 1 |
other | syndrome | 1 |
others | coronavirus | 1 |
others | covid-19 | 1 |
others | patients | 1 |
others | result | 1 |
others | risk | 1 |
others | rna | 1 |
others | study | 1 |
positive | cov-2 | 1 |
positive | proteins | 1 |
positive | risk | 1 |
positive | study | 1 |
positives | patients | 1 |
positives | result | 1 |
potential | diseases | 1 |
potential | patient | 1 |
largest | % | 1 |
important | risks | 1 |
larger | treatment | 1 |
covid-19 | analyses | 1 |
covid-19 | cells | 1 |
covid-19 | et | 1 |
covid-19 | sars | 1 |
covid-19 | syndrome | 1 |
covid-19 | times | 1 |
different | analysis | 1 |
different | syndromes | 1 |
earlier | response | 1 |
earliest | coronavirus | 1 |
earliest | sample | 1 |
early | antibodies | 1 |
early | cell | 1 |
early | treatments | 1 |
first | responses | 1 |
first | syndrome | 1 |
high | antibodies | 1 |
high | cases | 1 |
high | result | 1 |
high | viruses | 1 |
higher | cases | 1 |
higher | results | 1 |
covid-19 | cell | 1 |
clinical | risks | 1 |
highest | % | 1 |
clinical | result | 1 |
- | resulted | 1 |
- | resulting | 1 |
- | risked | 1 |
acute | cell | 1 |
acute | risks | 1 |
acute | sample | 1 |
anti | cov | 1 |
anti | covid-19 | 1 |
antiviral | patients | 1 |
antiviral | rna | 1 |
antiviral | sars | 1 |
antivirals | sars | 1 |
antivirals | treatment | 1 |
available | analysis | 1 |
available | cov | 1 |
available | day | 1 |
available | patients | 1 |
available | study | 1 |
available | times | 1 |
clinical | cells | 1 |
clinical | protein | 1 |
higher | samples | 1 |
highest | day | 1 |
larger | infection | 1 |
important | infections | 1 |
important | syndromes | 1 |
inflammatory | ace2 | 1 |
inflammatory | antibody | 1 |
inflammatory | cases | 1 |
inflammatory | covid-19 | 1 |
inflammatory | infection | 1 |
inflammatory | infections | 1 |
inflammatory | results | 1 |
inflammatory | risk | 1 |
large | analysis | 1 |
large | cases | 1 |
large | day | 1 |
large | infection | 1 |
large | patients | 1 |
large | risk | 1 |
large | time | 1 |
large | times | 1 |
large | viruses | 1 |
larger | analyses | 1 |
larger | cell | 1 |
larger | covid-19 | 1 |
important | response | 1 |
important | day | 1 |
highest | protein | 1 |
important | covid-19 | 1 |
highest | response | 1 |
highest | sample | 1 |
human | resulted | 1 |
human | studied | 1 |
human | syndrome | 1 |
humans | ace2 | 1 |
humans | case | 1 |
humans | coronavirus | 1 |
humans | infection | 1 |
humans | patient | 1 |
humans | result | 1 |
humans | resulted | 1 |
humans | results | 1 |
humans | sampled | 1 |
humans | virus | 1 |
immune | analysis | 1 |
immune | antibodies | 1 |
immune | antibody | 1 |
immune | sars | 1 |
immune | treatment | 1 |
important | cases | 1 |
virals | . | 1 |